| Filed On | Filing |
|---|---|
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] |
| 27 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Elanco Animal Health Incorporated (the “Company”) held its annual meeting of shareholders on May 21, 2026. Voting results for each matter submitted to a vote at the 2026 annual meeting are provided below. |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
J.P. Morgan Healthcare Conference Jeff Simmons President & CEO January 13, 2026 |
| 09 Dec 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] |
| 03 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS AMENDMENT NO. 3 TO CREDIT AGREEMENT (this “Agreement”), dated as of October 31, 2025, is entered into among ELANCO ANIMAL HEALTH INCORPORATED, a corporation formed under the laws of Indiana (the “U.S. Borrower” or the “Borrower Repr... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] |
| 26 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This FIRST AMENDMENT TO RECEIVABLES LOAN AGREEMENT, dated as of June 25, 2025 (this “Amendment”), is entered into by and among Elanco Spear LLC, a Delaware limited liability company, as borrower (the “Borrower”), Elanco US Inc. (“Elanco”... |
| 28 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] |
| 21 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Elanco Animal Health Incorporated (the “Company”) held its annual meeting of shareholders on May 16, 2025. Voting results for each matter submitted to a vote at the 2025 annual meeting are provided below. |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] |
| 17 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
J.P. Morgan Healthcare Conference January 14, 2025 Jeff Simmons President & Chief Executive Officer |
| 12 Nov 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] |
| 16 Oct 2024 |
8-K: Regulation FD Disclosure
On October 15, 2024, representatives of Elanco Animal Health Incorporated (the “Company”) presented the abstract titled “Serologic response to core booster vaccinations in dogs treated with a novel JAK inhibitor” at the International Soc... |
Loading...